Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 986-991

  Crowther, Grace S ^a   Chilton, Caroline H ^a   Longshaw, Chris ^b   Todhunter, Sharie L ^a   Ewin, Duncan ^a   Vernon, Jonathan ^a   Karas, Andreas ^b   Wilcox, Mark H ^a,c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Astellas Pharma EMEA ^*  (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; CYTOTOXIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL GROWTH; BACTERIAL SPORE; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM; CLOSTRIDIA; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; ENTEROCOCCUS; HUMAN; IN VITRO STUDY; INTESTINE FLORA; LIMIT OF DETECTION; NONHUMAN; RECURRENT INFECTION; SIMULATION; VANCOMYCIN TOLERANT ENTEROCOCCI; ANTIBIOTIC RESISTANCE; BACTERIAL LOAD; BIOLOGICAL MODEL; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GASTROINTESTINAL TRACT; MICROBIOLOGY; MICROFLORA; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE;

ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GASTROINTESTINAL TRACT; HUMANS; MICROBIOTA; MODELS, BIOLOGICAL; RECURRENCE; VANCOMYCIN;

EID: 84964329343     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv453     Document Type: Article

References (18)

1. PHE. Updated Guidance on the Management and Treatment of Clostridium difficile Infection. 2013. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/321891/Clostridium_difficile_management_and_treatment.pdf.
2. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80: 867-8.
3. Larson HE, Price AB, Borriello SP. Epidemiology of experimental enterocecitis due to Clostridium difficile. J Infect Dis 1980; 142: 408-13.
4. Crowther GS, Baines SD, Todhunter SL et al. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J Antimicrob Chemother 2013; 68: 168-76.
5. Chilton CH, Crowther GS, Freeman J et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J Antimicrob Chemother 2014; 69: 451-62.
6. Crowther GS, Chilton CH, Todhunter SL et al. Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model. J Antimicrob Chemother 2014; 69: 2137-47.
7. Chilton CH, Freeman J, Crowther GS et al. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. J Antimicrob Chemother 2012; 67: 2434-7.
8. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005; 55: 974-82.
9. Chilton CH, Crowther GS, Baines SD et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother 2014; 69: 697-705.
10. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 5.0, 2015. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf.
11. Chilton CH, Crowther GS, Todhunter SL et al. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. J Antimicrob Chemother 2014; 69: 2426-33.
12. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
13. Musher DM, Logan N, Bressler AM et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009; 48: e41-6.
14. Al-Nassir WN, Sethi AK, Nerandzic MM et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47: 56-62.
15. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62: 1078-85.
16. Freeman J, Baines SD, Jabes D et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005; 56: 717-25.
17. Freeman J, Stott J, Baines SD et al. Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 2005; 56: 988-9.
18. Reid KC, Cockerill IF, Patel R. Clinical and epidemiological features of Enterococcus casseliflavus/flavescens and Enterococcus gallinarum bacteremia: a report of 20 cases. Clin Infect Dis 2001; 32: 1540-6.